Aspect's brain monitor shows promise for depression testing market:
This article was originally published in Clinica
Following its recent neuroscience technology deal with Boston Scientific, Aspect Medical Systems has released data to show that in depression patients its brain monitoring system was able to predict with 76% accuracy which individual being treated with antidepressant therapy would experience new or more severe thoughts of suicide. The research, conducted in the US at the Massachusetts General Hospital and Harvard Medical School, was initiated primarily to test the ability of Aspect's electroencephalogram (EEG)-analysing technology to predict treatment response to selective serotonin reuptake inhibitor (SSRI) medications. The findings were presented this month at the New Clinical Drug Evaluation Unit meeting in Boca Raton, Florida. Aspect, of Newton, Massachusetts, recently received $25m from Boston in a strategic alliance to develop neuroscience-related products.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.